CN119013281A - 作为apol1抑制剂的4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法 - Google Patents

作为apol1抑制剂的4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法 Download PDF

Info

Publication number
CN119013281A
CN119013281A CN202380032015.3A CN202380032015A CN119013281A CN 119013281 A CN119013281 A CN 119013281A CN 202380032015 A CN202380032015 A CN 202380032015A CN 119013281 A CN119013281 A CN 119013281A
Authority
CN
China
Prior art keywords
alkyl
group
optionally substituted
independently selected
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380032015.3A
Other languages
English (en)
Chinese (zh)
Inventor
T·J·森特
S·安格
M·A·布罗德尼
J·曹
J·科姆
L·A·达金
E·多尔基克
Z·加勒-戴
E·B·克吕格尔
S·南塔库马尔
J·H·奥尔森
A·J·希米祖
S·D·斯通
王皓轩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN119013281A publication Critical patent/CN119013281A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN202380032015.3A 2022-02-08 2023-02-08 作为apol1抑制剂的4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法 Pending CN119013281A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263307876P 2022-02-08 2022-02-08
US63/307876 2022-02-08
PCT/US2023/012578 WO2023154309A1 (en) 2022-02-08 2023-02-08 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same

Publications (1)

Publication Number Publication Date
CN119013281A true CN119013281A (zh) 2024-11-22

Family

ID=85685675

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380032015.3A Pending CN119013281A (zh) 2022-02-08 2023-02-08 作为apol1抑制剂的4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法

Country Status (7)

Country Link
US (1) US20250136612A1 (cg-RX-API-DMAC7.html)
EP (1) EP4476228A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025505644A (cg-RX-API-DMAC7.html)
CN (1) CN119013281A (cg-RX-API-DMAC7.html)
AU (1) AU2023218939A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251124A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023154309A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3897833T (lt) 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
EP4097083A1 (en) 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
EP4146633A4 (en) 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1
JP2023530271A (ja) 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤及びこれを使用する方法
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2020414A1 (en) * 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
HUP2200468A1 (hu) * 2020-04-29 2023-03-28 X Chem Zrt IAP antagonisták és gyógyászati alkalmazásuk
US20230014907A1 (en) * 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same

Also Published As

Publication number Publication date
WO2023154309A1 (en) 2023-08-17
JP2025505644A (ja) 2025-02-28
US20250136612A1 (en) 2025-05-01
CA3251124A1 (en) 2023-08-17
AU2023218939A1 (en) 2024-08-22
EP4476228A1 (en) 2024-12-18

Similar Documents

Publication Publication Date Title
US12421249B2 (en) Inhibitors of APOL1 and methods of using same
WO2023154309A1 (en) 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same
KR101624365B1 (ko) C형 간염 바이러스 억제제
CN108623615B (zh) 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用
CN102378762B (zh) 丙型肝炎病毒抑制剂
AU2012214767B2 (en) Hepatitis C virus inhibitors
CN118632850A (zh) Apol1的螺环抑制剂和其使用方法
EP4129996A1 (en) Novel aminopyrimidine egfr inhibitor
CN119343353A (zh) 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法
US20220175788A1 (en) 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes
JP2018521005A (ja) ウレア誘導体、またはその薬理学的に許容される塩
CN119212986A (zh) 作为apol1的抑制剂的螺哌啶衍生物及其使用方法
TW201249834A (en) Hepatitis C virus inhibitors
IL301567A (en) A compound as an AKT KINASE inhibitor
WO2023077070A1 (en) Rxfp1 agonists
EA018331B1 (ru) Пирролопиримидинкарбоксамиды
JP7843780B2 (ja) 癌の処置に使用するための2,8-ジヒドロピラゾロ[3,4-b]インドール誘導体
OA21175A (en) Inhibitors of APOL1 and methods of using same.
SG187561A1 (en) 2,3,5-trisubstituted thiophene compounds and uses thereof
HK40030345B (en) Morpholinylpyridone compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination